Delayed
Hong Kong S.E.
21:20:04 2024-04-28 EDT
|
5-day change
|
1st Jan Change
|
7.27
HKD
|
+0.97%
|
|
+1.11%
|
-47.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
24,871
|
18,009
|
26,071
|
26,593
|
30,844
|
16,259
|
-
|
-
|
Enterprise Value (EV)
1 |
24,200
|
15,927
|
24,362
|
24,000
|
27,803
|
12,920
|
12,469
|
11,317
|
P/E ratio
|
12.7
x
|
7.12
x
|
8.68
x
|
8.17
x
|
12.8
x
|
9.3
x
|
8.06
x
|
5.86
x
|
Yield
|
3.15%
|
5.68%
|
4.63%
|
4.93%
|
3.11%
|
4.69%
|
5.1%
|
6.99%
|
Capitalization / Revenue
|
4.09
x
|
2.59
x
|
3.13
x
|
2.91
x
|
3.85
x
|
2.04
x
|
1.77
x
|
1.49
x
|
EV / Revenue
|
3.98
x
|
2.29
x
|
2.92
x
|
2.62
x
|
3.47
x
|
1.62
x
|
1.35
x
|
1.04
x
|
EV / EBITDA
|
9.45
x
|
5.36
x
|
7.23
x
|
6.35
x
|
9.34
x
|
5.88
x
|
4.81
x
|
3.13
x
|
EV / FCF
|
9.61
x
|
6.78
x
|
10.6
x
|
7.93
x
|
12.7
x
|
6.5
x
|
6.12
x
|
4.1
x
|
FCF Yield
|
10.4%
|
14.8%
|
9.48%
|
12.6%
|
7.86%
|
15.4%
|
16.3%
|
24.4%
|
Price to Book
|
2.63
x
|
1.63
x
|
2.04
x
|
1.82
x
|
1.99
x
|
1.01
x
|
0.93
x
|
0.86
x
|
Nbr of stocks (in thousands)
|
2,480,409
|
2,470,761
|
2,457,444
|
2,451,989
|
2,451,989
|
2,439,529
|
-
|
-
|
Reference price
2 |
10.03
|
7.289
|
10.61
|
10.85
|
12.58
|
6.665
|
6.665
|
6.665
|
Announcement Date
|
20-03-31
|
21-03-16
|
22-03-15
|
23-03-16
|
24-03-27
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6,074
|
6,946
|
8,337
|
9,150
|
8,013
|
7,982
|
9,203
|
10,891
|
EBITDA
1 |
2,560
|
2,972
|
3,371
|
3,780
|
2,976
|
2,199
|
2,592
|
3,615
|
EBIT
1 |
2,356
|
2,763
|
3,151
|
3,552
|
2,746
|
2,012
|
2,386
|
3,434
|
Operating Margin
|
38.79%
|
39.78%
|
37.79%
|
38.82%
|
34.27%
|
25.2%
|
25.93%
|
31.53%
|
Earnings before Tax (EBT)
1 |
2,488
|
2,816
|
3,457
|
3,763
|
2,874
|
2,125
|
2,415
|
3,360
|
Net income
1 |
1,956
|
2,530
|
3,017
|
3,259
|
2,401
|
1,773
|
2,046
|
2,698
|
Net margin
|
32.2%
|
36.43%
|
36.19%
|
35.62%
|
29.96%
|
22.22%
|
22.23%
|
24.77%
|
EPS
2 |
0.7905
|
1.024
|
1.223
|
1.328
|
0.9792
|
0.7165
|
0.8268
|
1.137
|
Free Cash Flow
1 |
2,518
|
2,351
|
2,309
|
3,028
|
2,185
|
1,986
|
2,036
|
2,761
|
FCF margin
|
41.45%
|
33.84%
|
27.7%
|
33.1%
|
27.27%
|
24.89%
|
22.12%
|
25.35%
|
FCF Conversion (EBITDA)
|
98.35%
|
79.1%
|
68.5%
|
80.12%
|
73.43%
|
90.33%
|
78.55%
|
76.37%
|
FCF Conversion (Net income)
|
128.73%
|
92.89%
|
76.52%
|
92.92%
|
91%
|
112.01%
|
99.53%
|
102.35%
|
Dividend per Share
2 |
0.3154
|
0.4138
|
0.4910
|
0.5344
|
0.3917
|
0.3125
|
0.3398
|
0.4656
|
Announcement Date
|
20-03-31
|
21-03-16
|
22-03-15
|
23-03-16
|
24-03-27
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
3,109
|
3,108
|
3,838
|
3,843
|
4,494
|
4,448
|
4,703
|
4,610
|
3,403
|
3,807
|
4,166
|
4,566
|
4,631
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
1,634
|
1,517
|
1,822
|
1,730
|
1,873
|
873.5
|
1,093
|
1,126
|
1,281
|
1,348
|
Operating Margin
|
-
|
-
|
-
|
42.52%
|
33.76%
|
40.97%
|
36.79%
|
40.62%
|
25.67%
|
28.71%
|
27.04%
|
28.06%
|
29.1%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-31
|
20-08-12
|
21-03-16
|
21-08-23
|
22-03-15
|
22-08-22
|
23-03-16
|
23-09-12
|
24-03-27
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
671
|
2,081
|
1,708
|
2,593
|
3,041
|
3,339
|
3,790
|
4,942
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2,518
|
2,351
|
2,309
|
3,028
|
2,185
|
1,986
|
2,036
|
2,761
|
ROE (net income / shareholders' equity)
|
21.9%
|
24.7%
|
25.4%
|
23.8%
|
15.9%
|
11.1%
|
12.2%
|
16%
|
ROA (Net income/ Total Assets)
|
18%
|
21.2%
|
21.2%
|
19.4%
|
13.5%
|
9.42%
|
10.3%
|
12.7%
|
Assets
1 |
10,839
|
11,936
|
14,255
|
16,781
|
17,742
|
18,817
|
19,816
|
21,168
|
Book Value Per Share
2 |
3.820
|
4.460
|
5.190
|
5.950
|
6.330
|
6.620
|
7.130
|
7.770
|
Cash Flow per Share
2 |
1.030
|
1.090
|
1.010
|
1.450
|
1.020
|
0.6900
|
0.7100
|
1.070
|
Capex
1 |
340
|
341
|
185
|
525
|
318
|
630
|
687
|
774
|
Capex / Sales
|
5.61%
|
4.92%
|
2.22%
|
5.74%
|
3.97%
|
7.9%
|
7.46%
|
7.11%
|
Announcement Date
|
20-03-31
|
21-03-16
|
22-03-15
|
23-03-16
|
24-03-27
|
-
|
-
|
-
|
Last Close Price
6.665
CNY Average target price
10.08
CNY Spread / Average Target +51.30% Consensus |
1st Jan change
|
Capi.
|
---|
| -47.47% | 2.24B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|